Lixa exists to solve the global problem of antimicrobial resistance.
Our technologies are broadly applicable across human, animal, plant, marine and industrial applications.
.png)
A moonshot to fix the broken antibiotic business model
By 2050, Antimicrobial Resistance (AMR) is forecast to have caused 39M deaths and US$100 trillion in economic loss (1).
​
80% of the US$71bn antibiotics market (2) are off-patent, generic drugs (3) - highly unusual in the pharmaceutical industry.
​
Patented antibiotics are expensive, toxic, costly to develop (>AUS$1n) (4) and get shelved as "last resort" to avoid new superbugs emerging.
​
Antibiotics are essential but, intrinsically, evoke resistance.
It's time to build on the foundations laid by antibiotics and multiply their effect with resistance breakers - towards a new antimicrobial paradigm.
​
4) Nature, 2024
Resistance is a multifaceted problem
Bacterial resistance is a growing issue, not only against antibiotic drugs but against biocides that control bacteria in our environment.
​
This resistance is exponentially increased by biofilms, a difficult to remove matrix or slime that prevents treatments from reaching their target.
Our proprietary ingredients not only dismantle the biofilm but disable resistance mechanisms - targeting unmet needs in acute and chronic, planktonic and biofilm, resistant contaminations and infections. ​
.png)
35% of sepsis deaths associated with resistant bacteria
Acute infections and sepsis
US$34bn annual economic cost
40% additional fuel consumption
Marine fouling
80% of chronic infections associated with bacterial biofilms
Chronic infections
US$2.7T annual economic cost from bacterial associated corrosion
Industrial corrosion
